CA2229479A1 - Method of promoting angiogenesis - Google Patents
Method of promoting angiogenesisInfo
- Publication number
- CA2229479A1 CA2229479A1 CA002229479A CA2229479A CA2229479A1 CA 2229479 A1 CA2229479 A1 CA 2229479A1 CA 002229479 A CA002229479 A CA 002229479A CA 2229479 A CA2229479 A CA 2229479A CA 2229479 A1 CA2229479 A1 CA 2229479A1
- Authority
- CA
- Canada
- Prior art keywords
- relaxin
- treatment
- administration
- recombinant human
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2221—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Relaxin is useful for promoting angiogenesis and the treatment of infections or ischemic wounds where the injury results from lack of oxygen due to poor circulation.
Claims (22)
1. A method for treating an infection or ischemic wound in a mammal in need thereof comprising administering a therapeutically effective amount of relaxin.
2. The method of treatment of Claim 1 comprising the administration of relaxin in an amount sufficient to maintain a serum concentration of at least about 1 ng/ml.
3. The method of treatment of Claim 1 comprising the administration of recombinant human relaxin (H2).
4. The method of treatment of Claim 2 comprising the administration of recombinant human relaxin (H2).
5. The method of treatment of Claim 3 wherein said relaxin is administered parenterally.
6. The method of treatment of Claim 5 wherein said relaxin is administered by subcutaneous injection.
7. The method of treatment of Claim 3 wherein said relaxin is administered by inhalation to the patient's respiratory tract.
8. The method of treatment of Claim 3 wherein said infection or ischemic wound is one where the injury is the result from lack of oxygen due to poor circulation.
9. The method of treatment of Claim 8 wherein said lack of oxygen due to poor circulation is the result of a disease.
10. The method of treatment of Claim 9 wherein the disease is scleroderma or diabetes.
11. The method of treatment of Claim 1 wherein the wound is an ischemic ulcer.
12. A method for promoting angiogenesis in a mammal in need thereof comprising administering a therapeutically effective amount of relaxin.
13. The method of Claim 12 comprising the administration of relaxin in an amount sufficient to maintain a serum concentration of at least about 1 ng/ml.
14. The method of Claim 12 comprising the administration of recombinant human relaxin (H2).
15. The method of Claim 13 comprising the administration of recombinant human relaxin (H2).
16. The method of Claim 14 wherein said relaxin is administered parenterally.
17. The method of Claim 16 wherein said relaxin is administered by subcutaneous injection.
18. The method of Claim 14 wherein said relaxin is administered by inhalation to the patient's respiratory tract.
19. A method of using relaxin for the manufacture of a medicant for the treatment of an infection or ischemic wound.
20. The method of Claim 19 wherein the relaxin is recombinant human relaxin (H2).
21. A method of using relaxin for the manufacture of a medicant for the promotion of angiogenesis.
22. The method of Claim 21 wherein the relaxin is recombinant human relaxin (H2).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US235595P | 1995-08-15 | 1995-08-15 | |
US60/002,355 | 1995-08-15 | ||
PCT/US1996/013321 WO1997006814A1 (en) | 1995-08-15 | 1996-08-15 | Method of promoting angiogenesis |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2229479A1 true CA2229479A1 (en) | 1997-02-27 |
CA2229479C CA2229479C (en) | 2010-03-30 |
Family
ID=21700396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2229479A Expired - Lifetime CA2229479C (en) | 1995-08-15 | 1996-08-15 | Method of promoting angiogenesis |
Country Status (9)
Country | Link |
---|---|
US (3) | US6211147B1 (en) |
EP (1) | EP0845992B1 (en) |
JP (1) | JP4568383B2 (en) |
AT (1) | ATE228004T1 (en) |
AU (1) | AU6777196A (en) |
CA (1) | CA2229479C (en) |
DE (1) | DE69624925T2 (en) |
ES (1) | ES2187667T3 (en) |
WO (1) | WO1997006814A1 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2397200C (en) * | 2000-02-09 | 2010-11-23 | Connetics Corporation | Use of relaxin to treat diseases related to vasoconstriction |
ITRM20020119A1 (en) * | 2002-03-05 | 2003-09-05 | Geymonat Spa | COMPOSITIONS CONTAINING PLGF FOR PHARMACEUTICAL AND COSMETIC USE. |
US7878978B2 (en) * | 2004-03-18 | 2011-02-01 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Use of relaxin to increase arterial compliance |
CA2559745C (en) * | 2004-03-19 | 2010-11-02 | Bas Medical, Inc. | Use of relaxin to increase arterial compliance |
CA2563433C (en) * | 2004-04-30 | 2010-07-13 | Bas Medical, Inc. | Methods and compositions for control of fetal growth via modulation of relaxin |
US7893244B2 (en) * | 2005-04-12 | 2011-02-22 | Intradigm Corporation | Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases |
CA2604441A1 (en) * | 2005-04-12 | 2006-10-19 | Intradigm Corporation | Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases |
US20060281669A1 (en) * | 2005-06-13 | 2006-12-14 | Yue Samuel K | Method and compositions for the treatment of diabetes and related complications |
WO2007027168A1 (en) * | 2005-08-29 | 2007-03-08 | Carrier Corporation | Compressor muffler |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
CA2724542A1 (en) * | 2008-05-16 | 2009-11-19 | Corthera, Inc. | Method of administering relaxin to reduce cervical dilation |
MX2010012450A (en) | 2008-05-16 | 2011-03-21 | Corthera Inc Star | Treating dyspnea associated with acute heart failure with relaxin. |
EP2278993A4 (en) * | 2008-05-16 | 2012-09-12 | Corthera Inc | Method of promoting wound healing |
BRPI0805852A8 (en) * | 2008-09-05 | 2021-06-29 | Univ Rio De Janeiro | protein acid polymers, production processes, use of protein acid polymers, pharmaceutical composition and treatment method |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
CA2737461A1 (en) | 2008-09-19 | 2010-03-25 | Tandem Diabetes Care, Inc. | Solute concentration measurement device and related methods |
AU2010278894B2 (en) | 2009-07-30 | 2014-01-30 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
MY162837A (en) | 2010-08-17 | 2017-07-31 | Ambrx Inc | Modified relaxin polypeptides and their uses |
US10493131B2 (en) * | 2011-08-31 | 2019-12-03 | University Of Florida Research Foundation, Incorporated | Materials and methods for modulating activity of bone marrow derived cells |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US9555186B2 (en) | 2012-06-05 | 2017-01-31 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
US9526762B1 (en) * | 2013-08-09 | 2016-12-27 | William Marsh Rice University | Multidomain peptides for promoting angiogenesis |
EP4011919A3 (en) | 2015-12-09 | 2022-10-12 | The Scripps Research Institute | Relaxin immunoglobulin fusion proteins and methods of use |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023321A (en) * | 1982-12-13 | 1991-06-11 | Howard Florey Institute Of Experimental Physiology & Medicine | Molecular cloning and characterization of a further gene sequence coding for human relaxin |
US5023088A (en) * | 1987-06-25 | 1991-06-11 | Alza Corporation | Multi-unit delivery system |
WO1989007945A1 (en) | 1988-02-26 | 1989-09-08 | Genentech, Inc. | Human relaxin formulation |
GB8907799D0 (en) * | 1989-04-06 | 1989-05-17 | Erba Carlo Spa | Heteroaryl-3-oxo-propanenitrile derivatives useful in the treatment of rheumatoid arthritis and other autoimmune diseases |
CA2051375C (en) | 1989-05-04 | 2000-09-12 | Dennis J. Henner | Process and compositions for the isolation of human relaxin |
US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US5478807A (en) | 1991-08-19 | 1995-12-26 | Genentech, Inc. | Use of relaxin in the treatment of bradycardia |
US5166191A (en) * | 1991-08-19 | 1992-11-24 | Genentech, Inc. | Use of relaxin in cardiovascular therapy |
US5952296A (en) | 1993-07-27 | 1999-09-14 | Bigazzi; Mario | Method of using relaxin as therapeutic or preventing agent |
US5811395A (en) * | 1995-06-07 | 1998-09-22 | Medical University Of South Carolina | Relaxin analogs and derivatives methods and uses thereof |
US5911997A (en) * | 1995-06-07 | 1999-06-15 | Connetics Corporation | Relaxin-like factor and methods and uses thereof |
US5753623A (en) * | 1995-06-07 | 1998-05-19 | Connetics Corporation | Method of treatment for depression |
-
1996
- 1996-08-15 JP JP50951597A patent/JP4568383B2/en not_active Expired - Lifetime
- 1996-08-15 ES ES96928212T patent/ES2187667T3/en not_active Expired - Lifetime
- 1996-08-15 US US08/698,359 patent/US6211147B1/en not_active Expired - Lifetime
- 1996-08-15 EP EP96928212A patent/EP0845992B1/en not_active Expired - Lifetime
- 1996-08-15 WO PCT/US1996/013321 patent/WO1997006814A1/en active IP Right Grant
- 1996-08-15 AU AU67771/96A patent/AU6777196A/en not_active Abandoned
- 1996-08-15 DE DE69624925T patent/DE69624925T2/en not_active Expired - Lifetime
- 1996-08-15 AT AT96928212T patent/ATE228004T1/en active
- 1996-08-15 CA CA2229479A patent/CA2229479C/en not_active Expired - Lifetime
-
2001
- 2001-02-08 US US09/780,758 patent/US6780836B2/en not_active Expired - Lifetime
-
2004
- 2004-04-05 US US10/818,859 patent/US20040192606A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP0845992A1 (en) | 1998-06-10 |
JP4568383B2 (en) | 2010-10-27 |
CA2229479C (en) | 2010-03-30 |
ATE228004T1 (en) | 2002-12-15 |
ES2187667T3 (en) | 2003-06-16 |
US20010018418A1 (en) | 2001-08-30 |
US20040192606A1 (en) | 2004-09-30 |
US6780836B2 (en) | 2004-08-24 |
DE69624925T2 (en) | 2003-09-04 |
DE69624925D1 (en) | 2003-01-02 |
EP0845992B1 (en) | 2002-11-20 |
AU6777196A (en) | 1997-03-12 |
US6211147B1 (en) | 2001-04-03 |
WO1997006814A1 (en) | 1997-02-27 |
JPH11511174A (en) | 1999-09-28 |
EP0845992A4 (en) | 2000-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2229479A1 (en) | Method of promoting angiogenesis | |
Davis et al. | Pyoderma gangrenosum: skin grafting after preparation with hyperbaric oxygen | |
IL98089A0 (en) | Pharmaceutical preparations for administration of biologically active substance to a mammal via a mucosal membrane | |
IL141494A0 (en) | Stable hypoxia inducible factor-1 alpha and method of use | |
SE9302308L (en) | protein Preparation | |
EP0317568A4 (en) | Use of Granulocyte Macrophage colony stimulating factor to prepare a medicament for treating bacterial infections. | |
ATE94763T1 (en) | DRUG FOR THE TREATMENT OF FIBROTIC DISORDER AND ANTIFIBROTIC COMPOUND. | |
EP1719522B1 (en) | Medicinal composition comprising TCF-II | |
RU2007110166A (en) | HUMAN HEALING METHODS BY INTRODUCING HUMAN IL-18 | |
Bissell et al. | Longitudinal banded pigmentation of nails in primary adrenal insufficiency | |
Lehtinen et al. | Modification of aspects of the endocrine response to tracheal intubation by lignocaine, halothane and thiopentone | |
MY106603A (en) | Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon | |
ELDER et al. | Exacerbation of subclinical myasthenia by occupational exposure to an anesthetic | |
SU1697807A1 (en) | Method for treating candidiasis lesions of oral cavity and lip mucous membrane | |
SU1697822A1 (en) | Method for treating exudative forms of sinusitis | |
SU1711894A1 (en) | Method for treating the decompensated forms of stenosing laryngotracheitis in children | |
RU2205659C1 (en) | Method for treating patients for bronchopulmonary pneumonia | |
RU1777875C (en) | Method for treatment of gastroduodenal ulcer | |
RU1803119C (en) | Method of extrauterine pregnancy treatment | |
Gaul et al. | Baromedical nursing combines critical, acute, chronic care | |
Fragen | What is MIR? | |
Xue-wei et al. | Verdoglobinuria phenomenon in severe electrical burns | |
RU2154484C2 (en) | Method of treatment of "diabetic foot" syndrome | |
Foldes | V. Anesthesia considerations in oral surgery and dentistry | |
RU1811404C (en) | Zoonotic dermal leishmaniasis treatment method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20160815 |
|
MKEX | Expiry |
Effective date: 20160815 |